可溶性纤维蛋白原2的研究进展  

The research progress of soluble fibrinogen-like protein 2

作　　者：孟胜兰 肖创清[2] MENG Shenglan;XIAO Chuangqing(Department of Clinical Laboratory,the Second Affiliated Hospital of Hunan Normal University,Changsha,Hunan 410003,China;Department of Clinical Laboratory,the 163th Hospital of PLA,Changsha,Human 410003,China)

机构地区：[1]湖南师范大学第二附属医院检验科,湖南长沙410003 [2]解放军第163医院检验科,湖南长沙410003

出　　处：《国际检验医学杂志》2019年第4期468-471,507,共5页International Journal of Laboratory Medicine

基　　金：国家科技支撑子课题(2015BAI 32H00)

摘　　要：可溶性纤维蛋白原2(sFGL2)是CD4+CD25+CD127lowTregs细胞的新型效应分子,具有免疫调节作用,对维持Tregs的活性及功能十分重要。sFGL2可通过FcγRⅡB受体,诱导B细胞的凋亡,抑制树突状细胞成熟,抑制T细胞活化增殖发挥免疫抑制作用。本文介绍了有关sFGL2的基因、结构、免疫调节机制,并探讨了sFGL2在病毒性肝炎、自身免疫性疾病、移植排斥、肿瘤、动脉粥样硬化等疾病中的研究进展。Soluble fibrinogen-like protein 2(sFGL2),is an novel effector secreted by the CD4^+CD25^+CD127^low Tregs cells and plays an important role in immunoregulation.It is critical for the maintenance of the activity and function of Tregs.It can induce the apoptosis of B cells,suppress the maturation of dendritic cells and suppress the activation and proliferation of T cells through the FcγRⅡB receptor.This review concluded the recent progress of the genes,structure,immunoregulatory effects of sFGL2,and discussed the clinical implications of sFGL2 in hepatitis,autoimmunity,transplantation,tumors and atherosclerosis.

关 键 词：可溶性纤维蛋白原2 调节性T细胞 研究进展 

分 类 号：R446.63[医药卫生—诊断学]